SOLVSolventum
$90.35+30% 1Y
$90.35
$62.4952 weeks$92.40
The business
How SOLV's business earns
Solventum earns 3.8% on the capital it employs against an estimated 9.0% cost of capital.
3.8%
Return on invested capital · cost of capital 9.0% · 5.2 points below the estimated cost of capital
- Operating margin
- 5.6%
Operating margin · Medical Instruments & Supplies median 7.2% · 12 months to Sep 30, 2026
- Cash conversion
- 0.74×
Cash conversion · 0.25× a year ago · operating cash flow divided by operating profit after tax
- Share count, year on year
- −2.6%
Share count, year on year · fewer shares than a year ago
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2022 | 21% |
| FY2023 | 21% |
| FY2024 | 13% |
| FY2025 | 26% |
Details›
- Gross margin12 months to Sep 30, 2026
- 55%
- Operating margin12 months to Sep 30, 2026
- 5.6%
- Net margin12 months to Sep 30, 2026
- 1.9%
- Free cash flow margin
- 0.00%
- R&D as % of revenue
- 8.9%
- Revenue, trailing twelve months
- $8.16B
- Free cash flow, trailing twelve months
- $0
- Net income, trailing twelve months
- $156M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 3.8%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Instruments & Supplies
The closest names by size in the same industry